Rifampicin
Small molecule targets CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5 via activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | RIMACTANE | — | 1973-05-09 – 1976-05-18 | fda.gov ↗ |
| Approved | US (FDA) | RIFADIN | — | 1971-05-21 | fda.gov ↗ |
Trials 365 · started per year
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-11-19 | Global Alliance for TB Drug Development | Results Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time tballiance.org ↗
The 100 mg SPaL regimen had greater activity against TB than the standard of care HRZE (isoniazid, rifampin, pyrazinamide, and ethambutol), indicating the potential to shorten treatment time for active TB. |
| 2011-05-20 | Daiichi Sankyo | Regulatory Daiichi Sankyo Receives Approval in Japan for Additional Indication of Rifadin(R) Capsules for Nontuberculous Mycobacterial Disease daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it received approval in Japan for a supplemental New Drug Application (NDA) for an additional indication of Rifadin® (rifampicin) 150 mg capsules for nontuberculous mycobacterial disease including those caused by Mycobacterium avium and M. intracellulare. |
| 2010-12-15 | Daiichi Sankyo | Regulatory Daiichi Sankyo Submits Application for Additional Indication of Rifadin(R) Capsules for Nontuberculous Mycobacterial Disease daiichisankyo.com ↗
Tokyo, Japan (December 15, 2010) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), submitted a supplemental New Drug Application for an additional indication of Rifadin® (rifampicin) 150 mg capsules for nontuberculous mycobacterial (hereafter, NTM) disease based on well-established evidence. |
| 2010-07-26 | Sequella, Inc. | Results Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro sequella.com ↗ |
| 2008-03-31 | Lannett Company, Inc. | Regulatory Lannett Company Receives FDA Approval For Rifampin Capsules USPPDF Version investorroom.com ↗
“This approval bolsters our growing portfolio of manufactured pharmaceutical products,” said Arthur Bedrosian, president and chief executive officer of Lannett. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-19 | Global Alliance for TB Drug Development | Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time tballiance.org ↗ |
| 2011-05-20 | Daiichi Sankyo | Daiichi Sankyo Receives Approval in Japan for Additional Indication of Rifadin(R) Capsules for Nontuberculous Mycobacterial Disease daiichisankyo.com ↗ |
| 2010-12-15 | Daiichi Sankyo | Daiichi Sankyo Submits Application for Additional Indication of Rifadin(R) Capsules for Nontuberculous Mycobacterial Disease daiichisankyo.com ↗ |
| 2010-07-26 | Sequella, Inc. | Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro sequella.com ↗ |
| 2008-03-31 | Lannett Company, Inc. | Lannett Company Receives FDA Approval For Rifampin Capsules USPPDF Version investorroom.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 521 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifampicin | “Eligible patients were randomly assigned to receive intramuscular streptomycin (15 mg/kg once daily) and oral rifampicin (10 mg/kg once daily) for 8 weeks (8-week streptomycin...” PMID 20137805 ↗ Feb 2010258“INTERVENTIONS: Patients were randomized to receive daily treatment with 4 drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) given as an FDC (n = 798 patients) or...” PMID 21486974 ↗ Apr 2011 “This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol...” NCT06224036 ↗ “Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for...” NCT05046860 ↗ “45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue...” NCT00750841 ↗ “Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E)...” NCT04738812 ↗ “FDC intensive phase containing 150 mg of rifampicin, 75 mg of isoniazid not 300mg, 400 mg of pyrazinamide, and 275 mg of ethambutol, while FDC continuation phase containing...” NCT05005637 ↗ “This domain will focus on an antibiotic called rifampicin (also sometimes known as rifampin) as it is often added to other antibiotics to help treat artificial joint infections.” NCT06771050 ↗ “This study aimed to quantify the influence of food on the pharmacokinetics of isoniazid, rifampicin, ethambutol and pyrazinamide in TB patients starting anti-TB treatment.” PMID 26661397 ↗ Dec 2015 “SOC plus 6 months of tuberculosis treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, plus isoniazid and rifampicin for 4 subsequent months)” PMID 42468541 ↗ Jul 2026 “RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months” NCT04117698 ↗ |
| Known as | EREMFAT | “Rifampicin (Eremfat®) 600 mg orally in the evening for 10 days” NCT03082183 ↗1“oral rifampin administration (600 mg EREMFAT®)” NCT02507167 ↗ |
| Known as | RFP | “An open-label, randomized, 4-treatment, 6-sequence, 4-period crossover study was conducted to investigate the effects of rifampicin (RFP), an inhibitor of organic anionic...” PMID 38860384 ↗ Jun 20241“Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB” NCT04630145 ↗ |
| Known as | RIF | “In this open-labeled, randomized clinical trial, the Investigator will assess the safety and pharmacokinetics (PK) of model-optimized doses of rifampicin (RIF) with or without...” NCT02958709 ↗17“Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure.” PMID 30084943 ↗ Jan 2019 “Ritonavir-boosted darunavir (DRV/r) and dolutegravir (DTG) are affected by induction of metabolizing enzymes and efflux transporters caused by rifampicin (RIF).” PMID 35583344 ↗ May 2022 “Fusidic acid (FA) has been used for decades for bone infection, including prosthetic joint infection (PJI), often in combination with rifampin (RIF).” PMID 27682068 ↗ Sep 2016 “There is an unmet need for data concerning DTG once daily dosing in the presence of rifampicin (RIF), the widely used anti-tuberculosis antibiotic.” NCT03199690 ↗ “The purpose of this study is to evaluate the potential of high doses of rifampin (RIF) to shorten treatment for tuberculosis (TB)” NCT01408914 ↗ “WHO-recommended treatment requires 8-weeks of daily rifampicin (RIF) and clarithromycin (CLA) with wound care.” PMID 38573915 ↗ Apr 2024 “Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica.” NCT00816426 ↗ “A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)” NCT07002255 ↗ “Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.” NCT03474029 ↗ “3HR Regimen: Isoniazid (INH) + Rifampin (RIF), once daily, 90 total doses (3 months)” NCT07811518 ↗ |
| Known as | Rifadin | “Rifadin 600mg by mouth as two 300mg rifadin capsules” NCT04029584 ↗2“oral rifampicin (Rifadin with 10mg/kg/day)” NCT05821478 ↗ “Drug: Rifadin® (Rifampicin)” NCT03186482 ↗ |
| Known as | Rifampicin = Rifadin | “Rifampicin = Rifadin” NCT00696566 ↗ |
| Known as | rifampicin capsules | “Drug: Rifampicin Capsules” NCT02836821 ↗1“rifampicin capsules” NCT02331823 ↗ |
| Known as | rifampin | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗254“empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes...” NCT07332325 ↗ “A single dose of 600 mg rifampin, a potent OATP1B1/1B3 inhibitor, did not impact the PK of selatogrel to a clinically relevant extent suggesting that OATP1B1 and OATP1B3...” PMID 32166864 ↗ Mar 2020 “This is a phase II randomized open-label trial of high versus standard dose rifampin (RIF) with or without linezolid (LZD) for the first 4 weeks of treatment for Tuberculosis...” NCT04021121 ↗ “This domain will focus on an antibiotic called rifampicin (also sometimes known as rifampin) as it is often added to other antibiotics to help treat artificial joint infections.” NCT06771050 ↗ “The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.” NCT03561753 ↗ “in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16” NCT04510649 ↗ “using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]).” NCT02371681 ↗ “Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily” NCT01700790 ↗ “Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days.” NCT04553406 ↗ “2 months of isoniazid, rifampin, pyrazinamide, and ethambutol followed by 4 months of isoniazid and rifampin” NCT07608172 ↗ |
| Known as | Rifampin generic; Brand Rifadin, Rimatane | “Rifampin generic; Brand Rifadin, Rimatane” NCT01728363 ↗ |
| Known as | Rifampin=Rifadin | “Rifampin=Rifadin” NCT01074554 ↗ |
| Known as | Rimactane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02953847 ↗ |
| Known as | Rimapen | “The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days” NCT01854489 ↗ |
| Known as | RMP | “regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)” PMID 24903795 ↗ May 20142“Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)” NCT07058090 ↗ “Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)” NCT00495326 ↗ |
| Action | Activate | “Nevirapine, efavirenz and rifampicin are known inducers of cytochrome P450 3A4” NCT00620438 ↗ |
| Modality | Small molecule | “is a semi-synthetic compound” NCT00816426 ↗ |
| Route | Oral | “ciprofloxacin, clofazimine, ethambutol, and rifampin (all taken orally)” NCT00000641 ↗ |
| Target | CYP3A4 | “co-administration of a potent CYP3A4 inducer rifampin” PMID 25047139 ↗ Jul 2014 |